Monoclonal Or Polyclonal Antibody Or Immunoglobulin Or Fragment Thereof That Is Conjugated Or Adsorbed (e.g., Adsorbed To A Solid Support, Etc.) Patents (Class 530/391.1)
-
Publication number: 20140301977Abstract: The present invention provides methods for purifying a polypeptide from a composition comprising the polypeptide and at least one contaminant by overloading a chromatography material and eluting the product.Type: ApplicationFiled: November 2, 2012Publication date: October 9, 2014Inventors: Deepa Nadarajah, Amit Mehta
-
Publication number: 20140302535Abstract: Disclosed is a method of detecting a concentration of a biomarker in a human subject having or being at risk of developing Alzheimer's disease or Mild Cognitive Impairment (MCI). Also disclosed is a process for detecting a concentration of a biomarker in a human subject having or being at risk of developing Alzheimer's disease or Mild Cognitive Impairment (MCI) comprising (a) detecting a first concentration of lipocalin-PDS/TTR complex in a blood sample or urine sample from the subject, (b) determining a second concentration of PDS/TTR complex in a blood sample or urine sample from an unaffected individual, and (c) comparing the first and second concentrations, wherein a lower first concentration as compared to the second concentration is indicative of the subject having or being at risk of developing Alzheimer's disease.Type: ApplicationFiled: July 16, 2012Publication date: October 9, 2014Inventors: Mark A. Lovell, Bert C. Lynn
-
Publication number: 20140302043Abstract: The invention features a novel influenza antibody that specifically binds to influenza hemagglutinin and reduces or inhibits hemagglutinin binding to sialic acid. The invention also provides methods, compositions, and kits featuring the novel antibody and its use in preventing or treating influenza infection.Type: ApplicationFiled: February 3, 2014Publication date: October 9, 2014Applicants: DUKE UNIVERSITY, CHILDREN'S HOSPITAL BOSTONInventors: James Whittle, Stephen C. Harrison, Barton F. Haynes, Hua-Xin Liao, M. Anthomy Moody, Thomas B. Kepler, Aaron G. Schmidt
-
Patent number: 8853365Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.Type: GrantFiled: December 20, 2011Date of Patent: October 7, 2014Assignee: ABBVIE Inc.Inventors: Chengbin Wu, Dominic J. Ambrosi, Chung-ming Hsieh, Tariq Ghayur
-
Publication number: 20140295437Abstract: The present invention provides methods and non-fluorescent carbocyanine quencher compounds having the general formula: Wherein the A moiety is a substituted pyridinium, unsubstituted pyridinium, substituted quinolinium, unsubstituted quinolinium, substituted benzazolium, unsubstituted benzazolium, substituted indolinium, or substituted indolinium. The invention further provides luminescent donor molecule-quencher pairs and luminescent donor molecule-quencher-luminescent acceptor molecule conjugates wherein the quencher is a cyanine compound of the present invention. The energy transfer pairs are used to detect an analyte of interest in a sample.Type: ApplicationFiled: December 17, 2013Publication date: October 2, 2014Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Rosaria HAUGLAND, Ching-Ying CHEUNG, Stephen YUE
-
Publication number: 20140294852Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.Type: ApplicationFiled: April 3, 2014Publication date: October 2, 2014Applicants: Ono Pharmaceutical Co., LTD.Inventors: Alan J. Korman, Mohan Srinivasan, Changyu Wang, Mark J. Selby, Bingliang Chen, Josephine M. Cardarelli, Haichun Huang
-
Publication number: 20140295521Abstract: A new use of a molecule comprising at least one moiety which is a biologically active protein and at least one moiety capable of binding to a serum albumin of a mammal is provided, for preparation of a medicament which elicits no or a reduced immune response upon administration to the mammal, as compared to the immune response elicited upon administration to the mammal of the biologically active protein per se. Also provided is a method of reducing or eliminating the immune response elicited upon administration of a biologically active protein to a human or non-human mammal, which comprises coupling the polypeptide to at least one moiety capable of binding to a serum albumin of the mammal.Type: ApplicationFiled: January 21, 2014Publication date: October 2, 2014Applicant: AFFIBODY ABInventor: Nina Herne
-
Publication number: 20140294762Abstract: The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.Type: ApplicationFiled: April 7, 2014Publication date: October 2, 2014Applicant: Novo Nordisk A/SInventors: Shawn DeFrees, David A. Zopf, Robert J. Bayer, David James Hakes, Caryn L. Bowe, Xi Chen
-
Patent number: 8846876Abstract: Disclosed herein are non-natural amino acids and polypeptides that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The non-natural amino acids, by themselves or as a part of a polypeptide, can include a wide range of possible functionalities, but typical have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid polypeptides that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such polypeptides. Typically, the modified non-natural amino acid polypeptides include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, including therapeutic, diagnostic, and other biotechnology uses.Type: GrantFiled: June 20, 2012Date of Patent: September 30, 2014Assignee: Abrx, Inc.Inventors: Zhenwei Miao, Junjie Liu, Thea Norman, Russell Driver
-
Patent number: 8846874Abstract: Disclosed is an IgG Fc fragment useful as a drug carrier. Also, the present invention discloses a recombinant vector expressing the IgG Fc fragment, a transformant transformed with the recombinant vector, and a method of preparing an IgG Fc fragment, comprising culturing the transformant. When conjugated to a certain drug, the IgG Fc fragment improves the in vivo duration of action of the drug and minimizes the in vivo activity reduction of the drug.Type: GrantFiled: November 13, 2004Date of Patent: September 30, 2014Assignee: Hanmi Science Co., LtdInventors: Sung Youb Jung, Jin Sun Kim, Geun Hee Yang, Se Chang Kwon, Gwan Sun Lee
-
Patent number: 8846875Abstract: Methods, systems and/or kits for the preparation, purification and isolation of oligonucleotide conjugates, comprising conjugation of modified antibodies or proteins with at least one modified oligonucleotide at greater than 80% efficiency to form oligonucleotide conjugates and isolating the oligonucleotide conjugates from the conjugation solution by binding the conjugates to an immobilized binder, wherein the binder may be a metal ion or an antibody.Type: GrantFiled: February 11, 2011Date of Patent: September 30, 2014Assignee: Solulink, Inc.Inventors: David A. Schwartz, Leopoldo G. Mendoza
-
Publication number: 20140288411Abstract: Magnetic resonance imaging contrast agents that include a plurality of gas vesicles configured to associate with a noble gas are provided. Also provided are magnetic resonance imaging methods that include administering to a subject a contrast agent that includes a plurality of gas vesicles, obtaining a magnetic resonance data of a target site of interest, and analyzing the data to produce a magnetic resonance image of the target site. The subject contrast agents and methods find use in magnetic resonance imaging applications.Type: ApplicationFiled: March 12, 2014Publication date: September 25, 2014Inventors: Mikhail Georgievich Shapiro, Richard Matthew Ramirez, Vikram Bajaj, Lindsay Joslyn Sperling, David Vernon Schaffer, Alexander Pines
-
Publication number: 20140287526Abstract: Nanotube based lateral flow test device described herein is a lateral flow based diagnostic device, which uses arrays of fragments of single wall carbon nanotubes as sensor to detect the biomarkers at ultralow concentration (below picogram per milliliter). The device is consisted of the following components: (1). an lateral flow strip which typically is consisted of a backing film laminated with conjugate/sample pads, nitrocellulose membrane, wicking pad, (2). the arrays of single wall carbon nanotube conjugate with antibody which is immobilized on the membrane of the lateral flow device as the test line, (3). pairs of micro-electrode are installed on top part of the cassette, (4). a cassette which holds the lateral flow strip. The device can be used in clinical environments for biomarker detection.Type: ApplicationFiled: July 3, 2013Publication date: September 25, 2014Inventors: Xue-Feng Wang, Qingqi Chen
-
Patent number: 8841425Abstract: New thiol and disulfide-containing maytansinoids bearing a mono or di-alkyl substitution on the ?-carbon atom bearing the sulfur atom are disclosed. Also disclosed are methods for the synthesis of these new maytansinoids and methods for the linkage of these new maytansinoids to cell-binding agents. The maytansinoid-cell-binding agent conjugates are useful as therapeutic agents, which are delivered specifically to target cells and are cytotoxic. These conjugates display vastly improved therapeutic efficacy in animal tumor models compared to the previously described agents.Type: GrantFiled: March 9, 2011Date of Patent: September 23, 2014Assignee: ImmunoGen, Inc.Inventors: Ravi V. J. Chari, Wayne C. Widdison
-
Publication number: 20140275487Abstract: The present invention relates to the field of G protein coupled receptor (GPCR) structural biology and signaling. In particular, the present invention relates to binding domains directed against and/or specifically binding to GPCR:G protein complexes. Also provided are nucleic acid sequences encoding such binding domains and cells expressing or capable of expressing such binding domains. The binding domains of the present invention can be used as universal tools for the structural and functional characterization of G-protein coupled receptors in complex with downstream heterotrimeric G proteins and bound to various natural or synthetic ligands, for investigating the dynamic features of G protein activation, as well as for screening and drug discovery efforts that make use of GPCR:G protein complexes.Type: ApplicationFiled: June 21, 2012Publication date: September 18, 2014Inventors: Jan Steyaert, Els Pardon, Toon Laeremans, Brian Kobilka, Søren Rasmussen, Sébastien Granier, Roger K. Sunahara
-
Publication number: 20140273153Abstract: The present disclosure provides a method of covalently modifying a biological macromolecule, the method comprising subjecting a reaction mixture comprising: (a) a biological macromolecule comprising one or more thiol groups; and (b) a molecule comprising one or more olefin or alkyne moieties to a radical reaction under conditions sufficient to produce the covalently modified biological macromolecule. The present disclosure also provides a method of covalently modifying a biological macromolecule, the method comprising subjecting a reaction mixture comprising: (a) a molecule comprising one or more thiol groups; and (b) a biological macromolecule comprising one or more olefin or alkyne moieties to a radical reaction under conditions sufficient to produce the covalently modified biological macromolecule. The present disclosure further provides a covalently modified biological macromolecule prepared by any of the disclosed methods.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Applicant: Mosaic Biosciences, Inc.Inventors: Alexei KAZANTSEV, Peter D. MARINER, Martin STANTON
-
Publication number: 20140272931Abstract: The present invention relates to monoclonal antibodies for the detection of HCV antigen. More specifically, the invention describes antibodies against HCV core antigen lipid binding domain and immunoassay methods, kits and compositions for use in detecting HCV infection.Type: ApplicationFiled: December 23, 2013Publication date: September 18, 2014Applicant: Abbott LaboratoriesInventors: Robert Ziemann, April Ahlberg, David Hawksworth, Bryan Tieman, A. Scott Muerhoff, Christopher Marohnic, Kathy Otis
-
Publication number: 20140272944Abstract: The present invention is a new and non-obvious method for the improved and simplified purification of nucleic acids.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Inventor: Gerard J. Gundling
-
Publication number: 20140271685Abstract: In various embodiments various cancer specific antibodies and immunoconjugates are provided. In certain embodiments the antibodies specifically bind and are internalized into a prostate cancer cell, where the antibodies specifically binds cells that express or overexpress a CD46, and where the antibodies specifically bind sushi domain 1 of said CD46 (CD46 CPP1).Type: ApplicationFiled: March 11, 2014Publication date: September 18, 2014Inventor: BIN LIU
-
Patent number: 8835611Abstract: Methods for preparing monomeric cytotoxic drug/carrier conjugates with a drug loading significantly higher than in previously reported procedures and with decreased aggregation and low conjugate fraction (LCF) are described. Cytotoxic drug derivative/antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described. Monomeric calicheamicin derivative/anti-CD22 antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described.Type: GrantFiled: February 13, 2012Date of Patent: September 16, 2014Assignee: Wyeth Holdings LLCInventors: Arthur Kunz, Justin Keith Moran, Joseph Thomas Rubino, Neera Jain, Eugene Joseph Vidunas, John McLean Simpson, Paul David Robbins, Nishith Merchant, John Francis Dijoseph, Mark Edward Ruppen, Nitin Krishnaji Damle, Andrew George Popplewell
-
Publication number: 20140256916Abstract: The invention relates to a companion diagnostic antibody-like binding protein based on the humanized monoclonal antibody, DS6, to be used as diagnostic tool for in vivo detection and quantification of the tumor-associated MUC1-sialoglycotope, CA6.Type: ApplicationFiled: February 5, 2014Publication date: September 11, 2014Inventors: Jochen Kruip, Susanta K. Sarkar, Mathias Gebauer, Christian Lange, Ingo Focken
-
Patent number: 8828399Abstract: Immunogenic compositions and prophylactic or therapeutic vaccines for use in protecting and treating against human cytomegalovirus (CMV) are disclosed. Subunit vaccines comprising a human CMV protein complex comprising pUL128 or pUL130, and nucleic acid vaccines comprising at least one nucleic acid encoding a CMV protein complex comprising pUL128 or pUL130 are described. Also disclosed are therapeutic antibodies reactive against a CMV protein complex comprising pUL128 or pUL130, as well as methods for screening compounds that inhibit CMV infection of epithelial and endothelial cells, methods for immunizing a subject against CMV infection, methods for determining the capability of neutralizing antibodies to inhibit CMV infection of cell types other than fibroblasts, and methods of diminishing an CMV infection.Type: GrantFiled: March 1, 2012Date of Patent: September 9, 2014Assignee: The Trustees of Princeton UniversityInventors: Thomas Shenk, Dai Wang
-
Patent number: 8828670Abstract: The invention relates to a method for producing monomeric or dimeric proteins or peptides containing internal or external disulfide bonds, comprising the following steps: a) a cell-free lysate, obtainable from eukaryotic cells, is provided, which contains functional microsomal vesicles, b) a nucleic acid coding the protein or peptide and additionally containing a signal sequence is added to the lysate, c) the lysate with the nucleic acid is held for a given time at a temperature in the range from 20 to 35° C., proteins or peptides formed with the nucleic acid being translocated into the microsomal vesicles, d) the microsomal vesicles are then dissolved, and the proteins or peptides obtained thereby are optionally separated from the lysate.Type: GrantFiled: July 10, 2012Date of Patent: September 9, 2014Assignee: RiNA Netzwerk RNA Technologien GmbHInventors: Helmut Merk, Wolfgang Stiege, Christine Gless, Michael Gerrits
-
Patent number: 8829150Abstract: The present invention discloses methods for polymerizing non-immunogenic haptens into immunogens, which then can be used to stimulate anti-hapten antibody production in animals. Specifically, haptens with amine and/or carboxylic groups are polymerized into macromolecules by using cross-linking reagents, and the derived haptenic polymers are used to immunize animals for the production of anti-hapten antibodies.Type: GrantFiled: September 19, 2013Date of Patent: September 9, 2014Assignee: National Taiwan Normal UniversityInventors: Che-Hsiung Lin, Yu-Chie Wang
-
Patent number: 8828400Abstract: Described is an antibody or an antigen binding fragment thereof specifically binding to a full or empty H-1 parvovirus capsid. Such an antibody is useful for various diagnostic and therapeutic methods, e.g., for the detection/therapy of an H-1 parvovirus infection during pregnancy since parvovirus affects about 1 in 400 pregnancies and may cause fetal loss or fetal hydrops.Type: GrantFiled: December 1, 2010Date of Patent: September 9, 2014Assignee: Deutsches Krebsforschungszentrum Siftung des Öffentlichen RechtsInventors: Barbara Leuchs, Kathrin Kürschner, Andrea Kuck, Marcus Müller, Silvia Münstermann, Jean Rommelaere
-
Publication number: 20140248271Abstract: This invention relates to isolated nucleic acids comprising genes of human chromosome 12q23-qter and the proteins encoded by these genes. Expression vectors and host cells containing such genes or fragments thereof, as well as antibodies to the proteins encoded by these nucleic acids are also included herein.Type: ApplicationFiled: February 6, 2014Publication date: September 4, 2014Applicant: OSCIENT PHARMACEUTICALS CORPORATIONInventors: Tim Keith, Randall Little, Paul Van Eerdewegh, Josée Dupuis, Richard Del Mastro, Jason Simon, Kristina Allen, Sunil Pandit
-
Publication number: 20140248295Abstract: Disclosed herein are glycan-modified anti-CD4 monoclonal antibodies with N-linked glycans attached to the variable region. Expression vectors and cell lines useful for the production of such antibodies, and use of such antibodies for HIV prevention and therapy are also disclosed.Type: ApplicationFiled: December 18, 2013Publication date: September 4, 2014Applicant: THE ROCKEFELLER UNIVERSITYInventors: Ruijiang Song, David D. Ho
-
Publication number: 20140249293Abstract: The present invention relates to methods for searching and identifying absent and rare peptide sequences from public databases and their uses in the treatment of pathological diseases. One embodiment of the present invention provides a method that includes: a) storing, in a memory or storage of a computing device, a set of at least one peptide sequence of fixed length; b) searching, by the computing device, for a peptide sequence from the set within at least one database having naturally-occurring amino acid sequences; and c) classifying, by the number of appearance in the database, the peptide sequence.Type: ApplicationFiled: January 26, 2012Publication date: September 4, 2014Applicant: Boise State UniversityInventor: Greg Hampikian
-
Patent number: 8822168Abstract: The present invention includes assays and kits for detecting the assembly of an RNA binding protein-RNA complex and for detecting the activity of an RNA binding protein.Type: GrantFiled: March 10, 2006Date of Patent: September 2, 2014Assignee: The Trustees of the University of PennsylvaniaInventors: Gideon Dreyfuss, Lili Wan, Elizabeth Ottinger
-
Patent number: 8821874Abstract: Disclosed herein is a method of treating dry eye with a KLK-13 antibody.Type: GrantFiled: July 22, 2013Date of Patent: September 2, 2014Assignee: Allergan, Inc.Inventors: Michael E. Stern, Christopher S. Schaumburg, Karyn F. Siemasko, Jianping Gao
-
Patent number: 8822645Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.Type: GrantFiled: July 8, 2009Date of Patent: September 2, 2014Assignee: AbbVie Inc.Inventors: Tariq Ghayur, Jijie Gu, Peter C. Isakson
-
Publication number: 20140243236Abstract: Certain disclosed embodiments of the present invention concern the synthesis, derivatization, conjugation to immunoglobulins and signal amplification based on discrete, relatively short polymers having plural reactive functional groups that react with plural molecules of interest. Reactive functional groups, such as hydrazides, may be derivatized with a variety of detectable labels, particularly haptens. The remaining reactive functional groups may be conjugated directly to a specific binding molecule, such as to the oxidized carbohydrate of the Fc region of the antibody. Disclosed conjugates display large signal amplification as compared to those based on molecules derivatized with single haptens, and are useful for assay methods, particularly multiplexed assays.Type: ApplicationFiled: April 23, 2014Publication date: August 28, 2014Applicant: Ventana Medical Systems, Inc.Inventors: Jerry W. Kosmeder, II, Casey A. Kernag, Donald Johnson, Christopher Bieniarz
-
Publication number: 20140243208Abstract: The invention encompasses compositions and methods for selecting aptamers.Type: ApplicationFiled: July 23, 2012Publication date: August 28, 2014Applicant: Mediomics, LLCInventors: Yie-Hwa Chang, Ling Tian, Rongsheng Wang
-
Publication number: 20140242618Abstract: The invention provides novel antibodies which specifically bind to the methylphenidate metabolite, ritalinic acid, enabling an immunoassay that can detect methyphenidate in biological samples for an extended period following its ingestion. The invention also describes novel conjugates and kits incorporating the antibodies.Type: ApplicationFiled: February 21, 2014Publication date: August 28, 2014Applicant: RANDOX LABORATORIES LIMITEDInventors: Philip Lowry, Elouard Benchikh, Ivan McConnell, Peter Fitzgerald
-
Publication number: 20140242723Abstract: Method of detecting Symmetrical dimethyl arginine (SDMA) in biological samples. SDMA analogs for generating anti-SDMA antibodies having little or no cross-reactivity with asymmetrical dimethyl arginine, arginine, and monomethylarginine. The analogs have a protected or free thiol (—SH) group or hydroxyl (—OH) group that allow them to be linked to a suitable conjugation target which can be, for example, a protein containing molecule of a label. The anti-SDMA antibodies can be used in diagnostic immunoassay for the diagnosis of SDMA associated disorders and/or diseases.Type: ApplicationFiled: February 28, 2014Publication date: August 28, 2014Applicant: IDEXX Laboratories, Inc.Inventors: Murthy V.S.N. Yerramilli, Mahalakshmi Yerramilli, Michael Atkinson, Kwok Kam Yeung
-
Patent number: 8815211Abstract: An object of the present invention is to provide a radioactive metal anti-cadherin antibody which is highly accumulated specifically in cancer tissue. Another object is to provide a cancer therapeutic agent having high anti-cancer effect and safety and a cancer diagnostic agent. The radioactive metal-labeled anti-cadherin antibody is obtained by binding a radioactive metallic element to an anti-cadherin antibody via a metal-chelating reagent.Type: GrantFiled: February 9, 2011Date of Patent: August 26, 2014Assignees: Fujifilm RI Pharma Co., Ltd., Perseus Proteomics Inc.Inventors: Akihiro Hino, Akio Nagano, Masahiko Watanabe, Tadasi Matsuura, Hirokazu Satoh, Fumiko Nomura, Katsuyuki Mitomo
-
Publication number: 20140234214Abstract: The present disclosure provides methods of treating a tauopathy, involving administering an anti-Tau antibody. The present disclosure also provides anti-Tau antibodies, and formulations comprising same, for use in the methods.Type: ApplicationFiled: January 14, 2014Publication date: August 21, 2014Applicant: iPierian, Inc.Inventors: Irene Griswold-Prenner, Nancy E. Stagliano, Vu Dang
-
Patent number: 8809005Abstract: A composition comprising a conjugate of an anti-idiotype antibody specifically binding to a CDR region of a parent antibody and method of using polyclonal human serum immunoglobulin of class E, G, M, or A, and the use of said composition as a standard in an immunoassay is presented.Type: GrantFiled: November 16, 2007Date of Patent: August 19, 2014Assignee: Hoffmann-La Roche Inc.Inventors: Kay-Gunnar Stubenrauch, Rudolf Vogel, Uwe Wessels
-
Patent number: 8809508Abstract: Diagnostic assays for the diagnosis of amyloidosis, in particular Alzheimer's disease, and related aspects. In particular, monoclonal antibodies and an antibody assay are provided.Type: GrantFiled: March 16, 2012Date of Patent: August 19, 2014Assignee: Probiodrug AGInventors: Martin Kleinschmidt, Stephan Schilling, Jens-Ulrich Rahfeld, Kristin Ebermann, Hans-Ulrich Demuth
-
Patent number: 8809501Abstract: The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a therapeutic protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime or hydrazone linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer, and wherein the conjugation is carried out in the presence of a nucleophilic catalyst.Type: GrantFiled: June 4, 2012Date of Patent: August 19, 2014Assignees: Baxter International Inc., Baxter Healthcare SAInventors: Juergen Siekmann, Stefan Haider, Hanspeter Rottensteiner, Peter Turecek
-
Publication number: 20140227287Abstract: [Task] To provide an anti-human NGF antibody or an antigen-binding fragment thereof that is excellent in safety by reducing the risk of side effects such as the effects on a fetus, thrombus formation, and joint-related adverse events such as RPOA while maintaining high neutralizing activity, and to provide means for preventing or treating various diseases in which human NGF is involved in the formation of pathological conditions, by using the antibody or the antibody-binding fragment thereof. [Means for Resolution] An anti-human NGF antibody Fab? fragment comprising a heavy-chain variable region consisting of an amino acid sequence represented by SEQ ID NO:6 and a light-chain variable region consisting of an amino acid sequence represented by SEQ ID NO:4.Type: ApplicationFiled: February 8, 2013Publication date: August 14, 2014Applicant: Astellas Pharma Inc.Inventors: Masazumi KAMOHARA, Hirotsugu Tanaka, Yukari Koya, Jun Takasaki, Atsuo Yonezawa, Eiji Yoshimi
-
Publication number: 20140227294Abstract: The present invention encompasses PRLR binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hPRLR and neutralize hPRLR activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hPRLR and for inhibiting hPRLR activity, e.g., in a human subject suffering from a disorder in which hPRLR activity is detrimental. Also included in the invention are anti-PRLR antibody drug conjugates (ADCs).Type: ApplicationFiled: December 23, 2013Publication date: August 14, 2014Applicant: ABBVIE INC.Inventors: Mark Anderson, Jieyi Wang, Archana Thakur, Debra Chao, Chung-Ming Hsieh, Qian Zhang, Edward B. Reilly, Enrico L. DiGiammarino, Kenton L. Longenecker, Russell A. Judge, David A. Egan, Charles W. Hutchins
-
Patent number: 8802103Abstract: Monoclonal antibodies that specifically bind to an extracellular domain of human Jagged 1 and inhibit growth of a tumor comprising cancer stem cells are described. Also described is a method of treating cancer that comprises administering a therapeutically effective amount of a monoclonal anti-Jagged 1 antibody.Type: GrantFiled: May 15, 2008Date of Patent: August 12, 2014Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin Gurney, Timothy Hoey, Sanjeev Satyal, Maureen Fitch Bruhns
-
Patent number: 8802088Abstract: The present invention relates to a composition which comprises tryptophan whereby 10 to 90%, preferably 20 to 80% of the tryptophan is present as free tryptophan or peptide-bound tryptophan and 10 to 90%, preferably 20 to 80% of the tryptophan is present as polypeptide-bound tryptophan.Type: GrantFiled: April 27, 2009Date of Patent: August 12, 2014Assignee: DSM IP Assets B.V.Inventors: Cinderalla C. Gerhardt, Luppo Edens
-
Publication number: 20140219919Abstract: The present disclosure provides proteins comprising antigen binding sites of antibodies that bind to interleukin-11 (IL-11) receptor alpha (IL-11R?) and uses thereof, e.g., in therapy.Type: ApplicationFiled: February 6, 2014Publication date: August 7, 2014Applicant: CSL LimitedInventors: Kirsten EDWARDS, Matthew HARDY, Veronika RAYZMAN, Michael WILSON
-
Publication number: 20140220626Abstract: Provided is a peptide containing a variable region and improved in production efficiency. The peptide contains a variable region to which an antigen-binding site is to be formed and has an amino acid sequence expressing a specific adsorption function to a solid phase at a site closer to the C-terminal than a heavy-chain variable region or at a site closer to the C-terminal than a light-chain variable region.Type: ApplicationFiled: November 22, 2013Publication date: August 7, 2014Applicants: National University Corporation Kyoto Institute of Technology, ENPLAS CORPORATIONInventors: Mitsuyasu Koike, Kyoko Hamasaki, Yuki Shiritani, Michimasa Kishimoto, Yoichi Kumada, Takuhito Ohse
-
Publication number: 20140212899Abstract: Provided is a method for noninvasive prediction or diagnosis of inflammation and/or infection in amniotic fluid leaked through the cervix into the vagina to predict the concentration of inflammatory markers in the amniotic fluid inside uterus by measuring the concentration of inflammatory markers (various cytokines). Further provided is a method for prediction or diagnosis of inflammation and/or infection in amniotic fluid by measuring the concentration of markers (IL-6, IL-1? IL-8, MCP-1, GRO-?) in the amniotic fluid leaked through the cervix into the vagina in patients with premature rupture of membranes. The method can be performed more stably on pregnant women, as compared to the conventional method for prediction or diagnosis of inflammation and/or infection using invasively collected amniotic fluid.Type: ApplicationFiled: September 5, 2012Publication date: July 31, 2014Applicants: OB MED, SNU R&DB FOUNDATIONInventors: Bo Hyun Yoon, Joong Shin Park, Jong Kwan Jun, Chan Wook Park
-
Publication number: 20140212426Abstract: Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.Type: ApplicationFiled: January 28, 2013Publication date: July 31, 2014Applicant: Janssen Biotech, Inc.Inventors: Mark Cunningham, Yiqing Feng, Katharine Heeringa, Jinquan Luo, Robert Rauchenberger, Mark Rutz, Lani San Mateo, Robert Sarisky, Vedrana Stojanovic-Susulic, Raymond Sweet, Fang Teng, Alexey Teplyakov, Sheng-Jiun Wu
-
Patent number: 8790651Abstract: An isolated antibody that specifically binds to at least one of canine Interleukin-31 (IL-31) or feline IL-31 is provided. Such antibodies can be in the form of diagnostic and/or veterinary compositions useful for treating a pruritic and/or allergic condition in dogs or cats.Type: GrantFiled: June 28, 2012Date of Patent: July 29, 2014Assignee: Zoetis LLCInventors: Gary F. Bammert, Steven A. Dunham
-
Patent number: 8790649Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to EGFR are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.Type: GrantFiled: October 28, 2011Date of Patent: July 29, 2014Assignee: ImmunoGen, Inc.Inventors: Julianto Setiady, Peter U. Park, Lingyun Rui, Thomas Chittenden, Gillian Payne